Free iron ions decrease indoleamine 2,3-dioxygenase expression and reduce IFNγ-induced inhibition of Chlamydia trachomatis infection

Microbial Pathogenesis

Volumn 46, Issue 6, 2009, Pages 289-297

  Krausse Opatz, Birgit ^a   Wittkop, Ulrike ^a   Gutzki, Frank M ^a   Schmidt, Cornelia ^a   Jürgens Saathoff, Barbara ^a   Meier, Sabine ^a   Beckmann, Bibiana ^a   Takikawa, Osamu ^b   Morgan, Michael A ^a   Tsikas, Dimitrios ^a   Stichtenoth, Dirk O ^a   Wagner, Annette D ^a   Zeidler, Henning ^a   Köhler, Lars ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Chlamydia trachomatis; Indoleamine 2,3 dioxygenase; Interferon ; Iron

Indexed keywords

DEFEROXAMINE; FERROUS ION; FERROUS SULFATE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; TRYPTOPHAN;

ARTICLE; BACTERIAL GROWTH; CELL LEVEL; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; IRON DEPLETION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TRYPTOPHAN METABOLISM;

CELL LINE; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; IONS; TRYPTOPHAN;

CHLAMYDIA; CHLAMYDIA TRACHOMATIS;

EID: 67349199663     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2009.03.001     Document Type: Article

References (43)

1. Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 338 (2005) 20-24
2. Grohmann U., Fallarino F., and Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24 (2003) 242-248
3. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., and Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
4. Krausse-Opatz B., Busmann A., Tammen H., Menzel C., Mohring T., Yondre N.L., et al. Peptidomic analysis of human peripheral monocytes persistently infected by Chlamydia trachomatis. Med Microbiol Immunol (Berl) 196 (2007) 103-114
5. Levitt D., and Barol J. The immunobiology of Chlamydia. Immunol Today 8 (1987) 246-251
6. Beatty W.L., Morrison R.P., and Byrne G.I. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 58 (1994) 686-699
7. Campbell L.A., Patton D.L., Moore D.E., Cappuccio A.L., Mueller B.A., and Wang S.P. Detection of Chlamydia trachomatis deoxyribonucleic acid in women with tubal infertility. Fertil Steril 59 (1993) 45-50
8. Gerard H.C., Branigan P.J., Schumacher Jr. H.R., and Hudson A.P. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol 25 (1998) 734-742
9. Du M.X., Sotero-Esteva W.D., and Taylor M.W. Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma. J Interferon Cytokine Res 20 (2000) 133-142
10. Tas S.W., Vervoordeldonk M.J., Hajji N., Schuitemaker J.H., van der Sluijs K.F., May M.J., et al. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 110 (2007) 1540-1549
11. Thomas S.R., Salahifar H., Mashima R., Hunt N.H., Richardson D.R., and Stocker R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol 166 (2001) 6332-6340
12. Thomas S.R., Terentis A.C., Cai H., Takikawa O., Levina A., Lay P.A., et al. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem 282 (2007) 23778-23787
13. Samelson-Jones B.J., and Yeh S.R. Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry 45 (2006) 8527-8538
14. Barnewall R.E., and Rikihisa Y. Abrogation of gamma interferon-induced inhibition of Ehrlichia chaffeensis infection in human monocytes with iron-transferrin. Infect Immun 62 (1994) 4804-4810
15. Dimier I.H., and Bout D.T. Interferon-gamma-activated primary enterocytes inhibit Toxoplasma gondii replication: a role for intracellular iron. Immunology 94 (1998) 488-495
16. Al-Younes H.M., Rudel T., Brinkmann V., Szczepek A.J., and Meyer T.F. Low iron availability modulates the course of Chlamydia pneumoniae infection. Cell Microbiol 3 (2001) 427-437
17. Raulston J.E. Response of Chlamydia trachomatis serovar E to iron restriction in vitro and evidence for iron-regulated chlamydial proteins. Infect Immun 65 (1997) 4539-4547
18. Ishihara T., Aga M., Hino K., Ushio C., Taniguchi M., Iwaki K., et al. Inhibition of Chlamydia trachomatis growth by human interferon-alpha: mechanisms and synergistic effect with interferon-gamma and tumor necrosis factor-alpha. Biomed Res 26 (2005) 179-185
19. Beatty W.L., Belanger T.A., Desai A.A., Morrison R.P., and Byrne G.I. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun 62 (1994) 3705-3711
20. Shemer Y., and Sarov I. Inhibition of growth of Chlamydia trachomatis by human gamma interferon. Infect Immun 48 (1985) 592-596
21. Daubener W., and MacKenzie C.R. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol 467 (1999) 517-524
22. Coles A.M., Reynolds D.J., Harper A., Devitt A., and Pearce J.H. Low-nutrient induction of abnormal chlamydial development: a novel component of chlamydial pathogenesis?. FEMS Microbiol Lett 106 (1993) 193-200
23. Pfefferkorn E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A 81 (1984) 908-912
24. Taylor M.W., and Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5 (1991) 2516-2522
25. Hatch T.P. Competition between Chlamydia psittaci and L cells for host isoleucine pools: a limiting factor in chlamydial multiplication. Infect Immun 12 (1975) 211-220
26. Allan I., Hatch T.P., and Pearce J.H. Influence of cysteine deprivation on chlamydial differentiation from reproductive to infective life-cycle forms. J Gen Microbiol 131 (1985) 3171-3177
27. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 32 Suppl. 1 (2002) 70-78
28. Alpert P.T. New and emerging theories of cardiovascular disease: infection and elevated iron. Biol Res Nurs 6 (2004) 3-10
29. Jones R.L., Peterson C.M., Grady R.W., Kumbaraci T., Cerami A., and Graziano J.H. Effects of iron chelators and iron overload on Salmonella infection. Nature 267 (1977) 63-65
30. Mossey R.T., and Sondheimer J. Listeriosis in patients with long-term hemodialysis and transfusional iron overload. Am J Med 79 (1985) 397-400
31. Ampel N.M., Van Wyck D.B., Aguirre M.L., Willis D.G., and Popp R.A. Resistance to infection in murine beta-thalassemia. Infect Immun 57 (1989) 1011-1017
32. Gordeuk V.R., McLaren C.E., MacPhail A.P., Deichsel G., and Bothwell T.H. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 87 (1996) 3470-3476
33. Gordeuk V.R., Delanghe J.R., Langlois M.R., and Boelaert J.R. Iron status and the outcome of HIV infection: an overview. J Clin Virol 20 (2001) 111-115
34. Gordeuk V.R., Thuma P.E., Brittenham G.M., Biemba G., Zulu S., Simwanza G., et al. Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg 48 (1993) 193-197
35. Cronje L., Edmondson N., Eisenach K.D., and Bornman L. Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions. FEMS Immunol Med Microbiol 45 (2005) 103-112
36. Olakanmi O., Britigan B.E., and Schlesinger L.S. Gallium disrupts iron metabolism of mycobacteria residing within human macrophages. Infect Immun 68 (2000) 5619-5627
37. Wirth M., Berthold E., Grashoff M., Pfutzner H., Schubert U., and Hauser H. Detection of mycoplasma contaminations by the polymerase chain reaction. Cytotechnology 16 (1994) 67-77
38. Krausse-Opatz B., Dollmann P., Zeidler H., Kuipers J.G., and Kohler L. Frequent contamination of Chlamydia trachomatis and Chlamydia pneumoniae strains with mycoplasma. Biological relevance and selective eradication of mycoplasma from chlamydial cultures with mupirocin. Med Microbiol Immunol (Berl) 189 (2000) 19-26
39. Caldwell H.D., Kromhout J., and Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 31 (1981) 1161-1176
40. Hess S., Rheinheimer C., Tidow F., Bartling G., Kaps C., Lauber J., et al. The reprogrammed host: Chlamydia trachomatis-induced up-regulation of glycoprotein 130 cytokines, transcription factors, and antiapoptotic genes. Arthritis Rheum 44 (2001) 2392-2401
41. Peirson S.N., Butler J.N., and Foster R.G. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 31 (2003) e73
42. Takikawa O., Kuroiwa T., Yamazaki F., and Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 263 (1988) 2041-2048
43. Haikin H., and Sarov I. Determination of specific IGA antibodies to varicella zoster virus by immunoperoxidase assay. J Clin Pathol 35 (1982) 645-649